Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GYRE NASDAQ:IMAB NASDAQ:MNMD NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$6.65-5.7%$7.92$6.11▼$19.00$660.99M1.878,879 shs103,460 shsIMABI-Mab$2.62+30.3%$2.13$0.60▼$3.44$163.82M1.38329,517 shs44.48 million shsMNMDMind Medicine (MindMed)$8.44-7.2%$7.82$4.70▼$10.44$686.78M2.491.21 million shs1.60 million shsZVRAZevra Therapeutics$11.11$10.11$6.19▼$13.16$607.49M1.871.36 million shs802,278 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics-5.67%-12.96%-14.74%-28.19%-54.04%IMABI-Mab+30.35%+24.17%+14.41%+176.43%+88.49%MNMDMind Medicine (MindMed)-7.15%-13.52%+19.21%+21.79%-8.86%ZVRAZevra Therapeutics0.00%-1.07%+18.07%+38.88%+71.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGYREGyre TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMABI-Mab2.514 of 5 stars3.75.00.00.00.61.70.0MNMDMind Medicine (MindMed)1.9031 of 5 stars3.61.00.00.02.20.80.6ZVRAZevra Therapeutics2.0711 of 5 stars3.61.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGYREGyre Therapeutics 3.00BuyN/AN/AIMABI-Mab 3.33Buy$6.00129.01% UpsideMNMDMind Medicine (MindMed) 3.22Buy$24.00184.36% UpsideZVRAZevra Therapeutics 3.11Buy$23.71113.45% UpsideCurrent Analyst Ratings BreakdownLatest IMAB, GYRE, MNMD, and ZVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.007/10/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $29.007/9/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.007/9/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.007/2/2025ZVRAZevra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.006/27/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.005/14/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/14/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGYREGyre Therapeutics$105.76M5.90$0.19 per share35.70$1.05 per share6.33IMABI-Mab$3.89M54.89N/AN/A$2.47 per share1.06MNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/AZVRAZevra Therapeutics$23.61M25.73N/AN/A$0.74 per share15.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGYREGyre Therapeutics$12.09M$0.02332.67∞N/A7.20%9.73%7.66%8/12/2025 (Estimated)IMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.53N/AN/AN/AN/A-47.29%-38.29%N/AZVRAZevra Therapeutics-$105.51M-$1.90N/A55.55N/A-226.78%-201.05%-53.55%8/12/2025 (Estimated)Latest IMAB, GYRE, MNMD, and ZVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/27/2025Q2 2025IMABI-Mab-$0.10N/AN/AN/AN/AN/A8/12/2025Q2 2025GYREGyre Therapeutics$0.03N/AN/AN/A$30.80 millionN/A8/12/2025Q2 2025ZVRAZevra Therapeutics$0.65N/AN/AN/A$22.49 millionN/A7/31/2025Q2 2025MNMDMind Medicine (MindMed)-$0.38-$0.50-$0.12-$0.50N/AN/A5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGYREGyre TherapeuticsN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGYREGyre TherapeuticsN/A3.603.19IMABI-MabN/A22.3522.35MNMDMind Medicine (MindMed)0.107.277.27ZVRAZevra Therapeutics1.463.022.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGYREGyre Therapeutics23.99%IMABI-Mab38.38%MNMDMind Medicine (MindMed)27.91%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipGYREGyre Therapeutics10.00%IMABI-Mab22.10%MNMDMind Medicine (MindMed)2.45%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGYREGyre Therapeutics4093.76 million84.38 millionNo DataIMABI-Mab38081.50 million63.49 millionOptionableMNMDMind Medicine (MindMed)4075.55 million73.70 millionOptionableZVRAZevra Therapeutics2054.68 million53.37 millionOptionableIMAB, GYRE, MNMD, and ZVRA HeadlinesRecent News About These CompaniesWhat is William Blair's Estimate for ZVRA Q3 Earnings?August 1 at 5:41 AM | marketbeat.comEquities Analysts Set Expectations for ZVRA FY2025 EarningsAugust 1 at 2:15 AM | americanbankingnews.comQ3 Earnings Forecast for ZVRA Issued By William BlairAugust 1 at 2:25 AM | americanbankingnews.comDoes Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?July 31 at 10:56 AM | zacks.comWhat is William Blair's Estimate for ZVRA FY2025 Earnings?July 31 at 6:52 AM | marketbeat.comZevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type CJuly 28, 2025 | globenewswire.comReadystate Asset Management LP Purchases 616,370 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)July 23, 2025 | marketbeat.comAIGH Capital Management LLC Has $10.77 Million Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)July 22, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Downgraded to Buy Rating by Wall Street ZenJuly 20, 2025 | marketbeat.comZevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)July 18, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.July 17, 2025 | marketbeat.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...July 16, 2025 | finanznachrichten.deAre You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great ChoiceJuly 16, 2025 | zacks.com5 Small Drug Stocks to Buy Amid Trump's New Tariff ThreatsJuly 16, 2025 | zacks.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and MetabolismJuly 16, 2025 | globenewswire.comZevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type CJuly 16, 2025 | quiverquant.comQZevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?July 16, 2025 | marketbeat.comQ2 EPS Forecast for Zevra Therapeutics Raised by AnalystJuly 16, 2025 | marketbeat.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | finance.yahoo.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | zacks.comHere's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)July 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMAB, GYRE, MNMD, and ZVRA Company DescriptionsGyre Therapeutics NASDAQ:GYRE$6.65 -0.40 (-5.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.65 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.I-Mab NASDAQ:IMAB$2.62 +0.61 (+30.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.54 -0.08 (-2.86%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Mind Medicine (MindMed) NASDAQ:MNMD$8.44 -0.65 (-7.15%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.62 +0.18 (+2.07%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Zevra Therapeutics NASDAQ:ZVRA$11.11 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.38 +0.27 (+2.43%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
